Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Yabao Pharmaceutical Group Co FCF Margin %?
Yabao Pharmaceutical Group CoSHSE:600351 -3.53%70 FCF Margin % is 30.99% as of Mar. 2026, which is 151% above its 10-year median of 12.34. GuruFocus rates SHSE:600351 with a GF Score™ of 70/100 and a GF Value™ of ¥5.53 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 963 Drug Manufacturers companies, Yabao Pharmaceutical Group Co ranks better than 94.18% on this metric.
The historical rank and industry rank for Yabao Pharmaceutical Group Co's FCF Margin % or its related term are showing as below:
SHSE:600351'
s FCF Margin % Range Over the Past 10 Years
Min: 2.44 Med: 12.34 Max: 26.08
Current: 26.08
During the past 13 years, the highest FCF Margin % of Yabao Pharmaceutical Group Co was 26.08%. The lowest was 2.44%. And the median was 12.34%.
SHSE:600351's FCF Margin % is ranked better than 94.18% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.55
vs SHSE:600351: 26.08
Yabao Pharmaceutical Group Co FCF Margin % Related Terms
Yabao Pharmaceutical Group Co FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Yabao Pharmaceutical Group Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yabao Pharmaceutical Group Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Yabao Pharmaceutical Group Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Yabao Pharmaceutical Group Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yabao Pharmaceutical Group Co (SHSE:600351) has a FCF Margin % of 30.99% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Yabao Pharmaceutical Group Co and its competitors. This is 151% above median its historical median of 12.34. Over the past decade, Yabao Pharmaceutical Group Co's FCF Margin % has ranged from 2.44 to 26.08. According to the industry distribution chart, Yabao Pharmaceutical Group Co ranks #56 out of 963 companies in the Drug Manufacturers industry, placing it in the top 5.8%.
Is Yabao Pharmaceutical Group Co's FCF Margin % too high?
Yabao Pharmaceutical Group Co's current FCF Margin % of 30.99% is 151% above median its 10-year median of 12.34. Over the past 10 years, this metric has ranged from a low of 2.44 to a high of 26.08. The Drug Manufacturers industry median FCF Margin % is 2.55. Yabao Pharmaceutical Group Co's value of 30.99% is 1115.3% above this industry median. Based on the distribution chart, Yabao Pharmaceutical Group Co ranks #56 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Yabao Pharmaceutical Group Co has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yabao Pharmaceutical Group Co's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Yabao Pharmaceutical Group Co ranks #56 out of 963 companies for FCF Margin %. This places Yabao Pharmaceutical Group Co in the top 6% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.55. Yabao Pharmaceutical Group Co's value of 30.99% is 1115.3% above this benchmark. Historically, Yabao Pharmaceutical Group Co's own FCF Margin % has ranged from 2.44 to 26.08 over the past decade. While the company's 10-year median is 12.34 vs. the industry median of 2.55, Yabao Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.55, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yabao Pharmaceutical Group Co's current FCF Margin % of 30.99% is 1115.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Yabao Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yabao Pharmaceutical Group Co's current FCF Margin % is 30.99%, which is 151% above median its own 10-year median of 12.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yabao Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co (SHSE:600351) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.53, compared to a current price of ¥6.56 — trading 18.6% above its estimated fair value. The current FCF Margin % is 30.99%, which is 151% above median its 10-year median of 12.34 and 1115.3% above the Drug Manufacturers industry median of 2.55. Yabao Pharmaceutical Group Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Yabao Pharmaceutical Group Co (SHSE:600351), the current FCF Margin % is 30.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yabao Pharmaceutical Group Co (SHSE:600351) Overvalued in 2026?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥6.56 is trading 18.6% above its estimated GF Value™ of ¥5.53.
GuruFocus considers Yabao Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SHSE:600351:
FCF Margin %: 30.99% (151% above median its 10-year median of 12.34)
GF Value™: ¥5.53 vs. price of ¥6.56 (18.6% above fair value)
Industry Position: 1115.3% above the Drug Manufacturers median (#56 of 963)
No single metric tells the full story. See the SHSE:600351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yabao Pharmaceutical Group Co Business Description
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
70GF Score
Get the complete analysis for SHSE:600351
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600351 has been successfully added to your 
